Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
2.010
-0.110 (-5.19%)
At close: Nov 20, 2024, 4:00 PM
2.110
+0.100 (4.98%)
After-hours: Nov 20, 2024, 4:50 PM EST
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $411.94 million as of November 21, 2024. Its market cap has decreased by -9.33% in one year.
Market Cap
411.94M
Enterprise Value
317.27M
1-Year Change
-9.33%
Ranking
Category
Stock Price
$2.01
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has decreased from $690.43M to $411.94M, a decrease of -40.34%. That is a compound annual growth rate of -11.68%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Nov 19, 2024 | 434.48M | 31.29% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | 1.00B | 45.15% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Aura Biosciences | 445.57M |
| Allogene Therapeutics | 444.50M |
| National Research | 442.05M |
| Aquestive Therapeutics | 439.48M |
| Korro Bio | 436.84M |
| Foghorn Therapeutics | 433.63M |
| Quanterix | 424.47M |
| Rigel Pharmaceuticals | 421.18M |